View More Recent Stories

Dec 6, 2020 11:00PM Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors
Nov 16, 2020 04:01PM Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences
Nov 15, 2020 10:00AM Atara Biotherapeutics to Present New Open-Label Extension Data, Including 15-Month Safety and Efficacy Data from Highest Dose Cohorts, in the Phase1a Study of ATA188 for Progressive Forms of Multiple
Nov 12, 2020 08:39AM ATARA Biotherapeutics (ATRA) Highlights New Preclinical Data on ATA3271
Nov 12, 2020 08:30AM Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35th Society for Immunotherapy of Cancer Annual Mee
Nov 9, 2020 04:01PM Atara Biotherapeutics Announces Third Quarter 2020 Financial Results and Operational Progress
Nov 2, 2020 04:01PM Atara Biotherapeutics to Announce Third Quarter 2020 Financial Results on Monday, November 9, 2020
Sep 14, 2020 08:30AM Atara Biotherapeutics To Present Clinical Data in Epstein-Barr Virus-Driven (EBV+) Acquired & Primary Immunodeficiency Lymphoproliferative Diseases (AID-LPD and PID-LPD) from Tab-Cel® Expanded Ac
Sep 11, 2020 08:02AM ATARA Biotherapeutics (ATRA) announces presentation of data from first part of ongoing Phase 1 study of ATA188 for treatment of progressive forms of multiple sclerosis
Sep 11, 2020 08:00AM Atara Biotherapeutics Announces All Progressive Multiple Sclerosis Patients with Sustained Disability Improvement at Six Months Confirmed Improvement at 12 Months in the Phase 1a Study of ATA188
Sep 8, 2020 07:01AM ATARA Biotherapeutics (ATRA) Announces FDA Clearance of IND for ATA2271
Sep 8, 2020 07:00AM Atara Biotherapeutics Announces FDA Clearance of IND for ATA2271, a Next-Generation Autologous Mesothelin-Targeted CAR T with Novel PD1DNR and 1XX Technologies Combined to Treat Solid Tumors
Sep 1, 2020 07:00AM Atara Biotherapeutics to Present 12-Month Data from All Four Cohorts in the Phase 1a Study of ATA188 in Progressive Multiple Sclerosis at MSVirtual2020
Aug 5, 2020 04:01PM Atara Biotherapeutics Announces Second Quarter 2020 Financial Results and Operational Progress
Jul 29, 2020 04:01PM Atara Biotherapeutics to Announce Second Quarter 2020 Financial Results on Wednesday, August 5, 2020
Jun 17, 2020 09:04AM ATARA Biotherapeutics (ATRA) Reports First Patient Enrolled in Randomized Place-Controlled Study of Allogeneic T-cell Therapy ATA188 in Progressive Forms of MS
Jun 17, 2020 08:47AM  Atara Biotherapeutics Announces First Patient Enrolled in Randomized Placebo-Controlled Study of Allogeneic T-cell Therapy ATA188 in Progressive Forms of Multiple Sclerosis
Jun 5, 2020 04:15PM Atara Biotherapeutics Announces its 2020 Annual Meeting of Stockholders Will Be Held on June 16, 2020 in Virtual Format
Jun 4, 2020 04:01PM Atara Biotherapeutics to Participate at Two Upcoming Conferences
May 26, 2020 07:05AM ATARA Biotherapeutics (ATRA) Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months with ATA188 in Patients with Progressive MS in Late-Breaking e-Poster at EAN
May 26, 2020 07:00AM Atara Biotherapeutics Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months with ATA188 in Patients with Progressive Multiple Sclerosis in Late-Breaking e-Poster at th
May 19, 2020 08:33AM ATARA Biotherapeutics (ATRA) to Present Late-Breaking ATA188 Data in Progressive Multiple Sclerosis at EAN
May 19, 2020 08:30AM Atara Biotherapeutics to Present Late-Breaking ATA188 Data in Progressive Multiple Sclerosis at 2020 European Academy of Neurology (EAN) Virtual Congress
May 18, 2020 04:30PM Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 15, 2020 09:38AM ATARA Biotherapeutics (ATRA) Announces Presentation of Late-Breaking Preclinical Data on ATA2271 at AACR
May 15, 2020 09:38AM Atara Biotherapeutics Announces Presentation of Late-Breaking Preclinical Data on ATA2271, a Next-Generation Autologous CAR T Immunotherapy Targeting Mesothelin, at the American Association for Cancer
May 14, 2020 04:05PM  Atara Biotherapeutics Names Cell Therapy & Oncology Leader Jakob Dupont, M.D. as Global Head of Research & Development
May 11, 2020 04:01PM Atara Biotherapeutics Announces Appointment of Cell & Gene Therapy Expert Maria Grazia Roncarolo, MD to Board of Directors
May 6, 2020 04:01PM Atara Biotherapeutics Announces First Quarter 2020 Financial Results and Operational Progress
View More Recent Stories